Selected research
Industry Research
AI Pharma Industry Research Report 2026
Market perspective
The global AI Pharma market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the AI Pharma market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the AI Pharma market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the AI Pharma market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of AI Pharma include Recursion, Insilico Medicine, Exscientia, BenevolentAI, Atomwise, Roivant Sciences, Schrödinger, Lantern Pharma and XtalPi, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global AI Pharma market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to AI Pharma.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
AI Pharma Market by Company
Recursion
Insilico Medicine
Exscientia
BenevolentAI
Atomwise
Roivant Sciences
Schrödinger
Lantern Pharma
XtalPi
Landos Biopharma
Relay Therapeutics
Accutar Biotech
Deep Genomics
Oncocross
AI Therapeutics
BioMap
METiS Pharmaceuticals
NeoX Biotech
StoneWise
Deep Intelligent Pharma
Gigaceuticals
Chemical.AI
Artivila
Galixir
Xbiome
AI Pharma Segment by Type
Self-developed Oipeline
Contract Research Organization (CRO)
Other
AI Pharma Segment by Application
Preclinical Stage (Optimization of Lead Compounds, etc.)
Clinical Trial Phase (Predicting Treatment Outcome, etc.)
AI Pharma Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI Pharma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of AI Pharma and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI Pharma.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of AI Pharma companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Self-developed Oipeline
- Contract Research Organization (CRO)
- Other
Applications
- Preclinical Stage (Optimization of Lead Compounds, etc.)
- Clinical Trial Phase (Predicting Treatment Outcome, etc.)
Companies covered
- Recursion
- Insilico Medicine
- Exscientia
- BenevolentAI
- Atomwise
- Roivant Sciences
- Schrödinger
- Lantern Pharma
- XtalPi
- Landos Biopharma
- Relay Therapeutics
- Accutar Biotech
- Deep Genomics
- Oncocross
- AI Therapeutics
- BioMap
- METiS Pharmaceuticals
- NeoX Biotech
- StoneWise
- Deep Intelligent Pharma
- Gigaceuticals
- Chemical.AI
- Artivila
- Galixir
- Xbiome
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 AI Pharma by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Self-developed Oipeline
- 2.2.3 Contract Research Organization (CRO)
- 2.2.4 Other
- 2.3 AI Pharma by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Preclinical Stage (Optimization of Lead Compounds, etc.)
- 2.3.3 Clinical Trial Phase (Predicting Treatment Outcome, etc.)
- 2.4 Assumptions and Limitations
3 AI Pharma Breakdown Data by Type
- 3.1 Global AI Pharma Historic Market Size by Type (2021-2026)
- 3.2 Global AI Pharma Forecasted Market Size by Type (2027-2032)
4 AI Pharma Breakdown Data by Application
- 4.1 Global AI Pharma Historic Market Size by Application (2021-2026)
- 4.2 Global AI Pharma Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global AI Pharma Market Perspective (2021-2032)
- 5.2 Global AI Pharma Growth Trends by Region
- 5.2.1 Global AI Pharma Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 AI Pharma Historic Market Size by Region (2021-2026)
- 5.2.3 AI Pharma Forecasted Market Size by Region (2027-2032)
- 5.3 AI Pharma Market Dynamics
- 5.3.1 AI Pharma Industry Trends
- 5.3.2 AI Pharma Market Drivers
- 5.3.3 AI Pharma Market Challenges
- 5.3.4 AI Pharma Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top AI Pharma Players by Revenue
- 6.1.1 Global Top AI Pharma Players by Revenue (2021-2026)
- 6.1.2 Global AI Pharma Revenue Market Share by Players (2021-2026)
- 6.2 Global AI Pharma Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of AI Pharma Head Office and Area Served
- 6.4 Global AI Pharma Players, Product Type & Application
- 6.5 Global AI Pharma Manufacturers Established Date
- 6.6 Global AI Pharma Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America AI Pharma Market Size (2021-2032)
- 7.2 North America AI Pharma Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America AI Pharma Market Size by Country (2021-2026)
- 7.4 North America AI Pharma Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe AI Pharma Market Size (2021-2032)
- 8.2 Europe AI Pharma Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe AI Pharma Market Size by Country (2021-2026)
- 8.4 Europe AI Pharma Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific AI Pharma Market Size (2021-2032)
- 9.2 Asia-Pacific AI Pharma Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific AI Pharma Market Size by Country (2021-2026)
- 9.4 Asia-Pacific AI Pharma Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America AI Pharma Market Size (2021-2032)
- 10.2 South America AI Pharma Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America AI Pharma Market Size by Country (2021-2026)
- 10.4 South America AI Pharma Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa AI Pharma Market Size (2021-2032)
- 11.2 Middle East & Africa AI Pharma Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa AI Pharma Market Size by Country (2021-2026)
- 11.4 Middle East & Africa AI Pharma Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Recursion
- 12.1.1 Recursion Company Information
- 12.1.2 Recursion Business Overview
- 12.1.3 Recursion Revenue in AI Pharma Business (2021-2026)
- 12.1.4 Recursion AI Pharma Product Portfolio
- 12.1.5 Recursion Recent Developments
- 12.2 Insilico Medicine
- 12.2.1 Insilico Medicine Company Information
- 12.2.2 Insilico Medicine Business Overview
- 12.2.3 Insilico Medicine Revenue in AI Pharma Business (2021-2026)
- 12.2.4 Insilico Medicine AI Pharma Product Portfolio
- 12.2.5 Insilico Medicine Recent Developments
- 12.3 Exscientia
- 12.3.1 Exscientia Company Information
- 12.3.2 Exscientia Business Overview
- 12.3.3 Exscientia Revenue in AI Pharma Business (2021-2026)
- 12.3.4 Exscientia AI Pharma Product Portfolio
- 12.3.5 Exscientia Recent Developments
- 12.4 BenevolentAI
- 12.4.1 BenevolentAI Company Information
- 12.4.2 BenevolentAI Business Overview
- 12.4.3 BenevolentAI Revenue in AI Pharma Business (2021-2026)
- 12.4.4 BenevolentAI AI Pharma Product Portfolio
- 12.4.5 BenevolentAI Recent Developments
- 12.5 Atomwise
- 12.5.1 Atomwise Company Information
- 12.5.2 Atomwise Business Overview
- 12.5.3 Atomwise Revenue in AI Pharma Business (2021-2026)
- 12.5.4 Atomwise AI Pharma Product Portfolio
- 12.5.5 Atomwise Recent Developments
- 12.6 Roivant Sciences
- 12.6.1 Roivant Sciences Company Information
- 12.6.2 Roivant Sciences Business Overview
- 12.6.3 Roivant Sciences Revenue in AI Pharma Business (2021-2026)
- 12.6.4 Roivant Sciences AI Pharma Product Portfolio
- 12.6.5 Roivant Sciences Recent Developments
- 12.7 Schrödinger
- 12.7.1 Schrödinger Company Information
- 12.7.2 Schrödinger Business Overview
- 12.7.3 Schrödinger Revenue in AI Pharma Business (2021-2026)
- 12.7.4 Schrödinger AI Pharma Product Portfolio
- 12.7.5 Schrödinger Recent Developments
- 12.8 Lantern Pharma
- 12.8.1 Lantern Pharma Company Information
- 12.8.2 Lantern Pharma Business Overview
- 12.8.3 Lantern Pharma Revenue in AI Pharma Business (2021-2026)
- 12.8.4 Lantern Pharma AI Pharma Product Portfolio
- 12.8.5 Lantern Pharma Recent Developments
- 12.9 XtalPi
- 12.9.1 XtalPi Company Information
- 12.9.2 XtalPi Business Overview
- 12.9.3 XtalPi Revenue in AI Pharma Business (2021-2026)
- 12.9.4 XtalPi AI Pharma Product Portfolio
- 12.9.5 XtalPi Recent Developments
- 12.10 Landos Biopharma
- 12.10.1 Landos Biopharma Company Information
- 12.10.2 Landos Biopharma Business Overview
- 12.10.3 Landos Biopharma Revenue in AI Pharma Business (2021-2026)
- 12.10.4 Landos Biopharma AI Pharma Product Portfolio
- 12.10.5 Landos Biopharma Recent Developments
- 12.11 Relay Therapeutics
- 12.11.1 Relay Therapeutics Company Information
- 12.11.2 Relay Therapeutics Business Overview
- 12.11.3 Relay Therapeutics Revenue in AI Pharma Business (2021-2026)
- 12.11.4 Relay Therapeutics AI Pharma Product Portfolio
- 12.11.5 Relay Therapeutics Recent Developments
- 12.12 Accutar Biotech
- 12.12.1 Accutar Biotech Company Information
- 12.12.2 Accutar Biotech Business Overview
- 12.12.3 Accutar Biotech Revenue in AI Pharma Business (2021-2026)
- 12.12.4 Accutar Biotech AI Pharma Product Portfolio
- 12.12.5 Accutar Biotech Recent Developments
- 12.13 Deep Genomics
- 12.13.1 Deep Genomics Company Information
- 12.13.2 Deep Genomics Business Overview
- 12.13.3 Deep Genomics Revenue in AI Pharma Business (2021-2026)
- 12.13.4 Deep Genomics AI Pharma Product Portfolio
- 12.13.5 Deep Genomics Recent Developments
- 12.14 Oncocross
- 12.14.1 Oncocross Company Information
- 12.14.2 Oncocross Business Overview
- 12.14.3 Oncocross Revenue in AI Pharma Business (2021-2026)
- 12.14.4 Oncocross AI Pharma Product Portfolio
- 12.14.5 Oncocross Recent Developments
- 12.15 AI Therapeutics
- 12.15.1 AI Therapeutics Company Information
- 12.15.2 AI Therapeutics Business Overview
- 12.15.3 AI Therapeutics Revenue in AI Pharma Business (2021-2026)
- 12.15.4 AI Therapeutics AI Pharma Product Portfolio
- 12.15.5 AI Therapeutics Recent Developments
- 12.16 BioMap
- 12.16.1 BioMap Company Information
- 12.16.2 BioMap Business Overview
- 12.16.3 BioMap Revenue in AI Pharma Business (2021-2026)
- 12.16.4 BioMap AI Pharma Product Portfolio
- 12.16.5 BioMap Recent Developments
- 12.17 METiS Pharmaceuticals
- 12.17.1 METiS Pharmaceuticals Company Information
- 12.17.2 METiS Pharmaceuticals Business Overview
- 12.17.3 METiS Pharmaceuticals Revenue in AI Pharma Business (2021-2026)
- 12.17.4 METiS Pharmaceuticals AI Pharma Product Portfolio
- 12.17.5 METiS Pharmaceuticals Recent Developments
- 12.18 NeoX Biotech
- 12.18.1 NeoX Biotech Company Information
- 12.18.2 NeoX Biotech Business Overview
- 12.18.3 NeoX Biotech Revenue in AI Pharma Business (2021-2026)
- 12.18.4 NeoX Biotech AI Pharma Product Portfolio
- 12.18.5 NeoX Biotech Recent Developments
- 12.19 StoneWise
- 12.19.1 StoneWise Company Information
- 12.19.2 StoneWise Business Overview
- 12.19.3 StoneWise Revenue in AI Pharma Business (2021-2026)
- 12.19.4 StoneWise AI Pharma Product Portfolio
- 12.19.5 StoneWise Recent Developments
- 12.20 Deep Intelligent Pharma
- 12.20.1 Deep Intelligent Pharma Company Information
- 12.20.2 Deep Intelligent Pharma Business Overview
- 12.20.3 Deep Intelligent Pharma Revenue in AI Pharma Business (2021-2026)
- 12.20.4 Deep Intelligent Pharma AI Pharma Product Portfolio
- 12.20.5 Deep Intelligent Pharma Recent Developments
- 12.21 Gigaceuticals
- 12.21.1 Gigaceuticals Company Information
- 12.21.2 Gigaceuticals Business Overview
- 12.21.3 Gigaceuticals Revenue in AI Pharma Business (2021-2026)
- 12.21.4 Gigaceuticals AI Pharma Product Portfolio
- 12.21.5 Gigaceuticals Recent Developments
- 12.22 Chemical.AI
- 12.22.1 Chemical.AI Company Information
- 12.22.2 Chemical.AI Business Overview
- 12.22.3 Chemical.AI Revenue in AI Pharma Business (2021-2026)
- 12.22.4 Chemical.AI AI Pharma Product Portfolio
- 12.22.5 Chemical.AI Recent Developments
- 12.23 Artivila
- 12.23.1 Artivila Company Information
- 12.23.2 Artivila Business Overview
- 12.23.3 Artivila Revenue in AI Pharma Business (2021-2026)
- 12.23.4 Artivila AI Pharma Product Portfolio
- 12.23.5 Artivila Recent Developments
- 12.24 Galixir
- 12.24.1 Galixir Company Information
- 12.24.2 Galixir Business Overview
- 12.24.3 Galixir Revenue in AI Pharma Business (2021-2026)
- 12.24.4 Galixir AI Pharma Product Portfolio
- 12.24.5 Galixir Recent Developments
- 12.25 Xbiome
- 12.25.1 Xbiome Company Information
- 12.25.2 Xbiome Business Overview
- 12.25.3 Xbiome Revenue in AI Pharma Business (2021-2026)
- 12.25.4 Xbiome AI Pharma Product Portfolio
- 12.25.5 Xbiome Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst